Robust IPO activity in 2026, with 237 U.S. deals already priced through late August and additional offerings scheduled through year-end, underpins elevated trader confidence that listings will occur before 2027. Recent pricings such as ADARx Pharmaceuticals on September 24 and multiple filings advancing toward September 30 debuts including Oura and Accelevation Holdings demonstrate continued momentum. The pipeline features high-profile names like Anthropic, with a public prospectus expected imminently and a potential November Nasdaq listing, alongside AI infrastructure and consumer issuers. Market dynamics reflect resilient risk appetite for growth stories despite elevated Treasury yields and selective investor scrutiny following the SpaceX mega-deal earlier in the year. Key near-term catalysts include the September 30 Oura pricing and Anthropic’s roadshow, which could further confirm listings before year-end.